Virtual Clinical Trials Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2024-2030)

Virtual Clinical Trials Market Size

Virtual Clinical Trials Market Trends & Drivers

Growing Government Support and Initiatives for Clinical Trials & Research

The government support and stringent regulations in the U.S. pertaining to clinical trials are expected to boost the adoption of decentralized platforms, tools, and solutions. In addition, governments of various developing countries are taking initiatives for increasing the number of clinical trials. This is being done by raising awareness regarding such programs and motivating patients to enroll in them.

For instance, the U.K. government has launched a clinical trial program, ACCORD, to fast-track the development of new drug candidates for hospitalized COVID-19 patients. The program, carried out by industry partners, academia, and the government, aims to reduce the time taken to complete clinical trials for new treatments from months to weeks. In addition, technological advancements are expected to help in reducing the overall trial duration and providing accurate results.

Therefore, the growing support from the government of various countries for clinical research & development and the increasing awareness regarding wearable devices that monitor various health markers and transmit the data to the research coordinator are expected to aid in the market growth in the coming years.

Pandemic Had Huge Positive Impact on Market Growth

COVID-19 has positively impacted the market, as during the global lockdowns, trials needed to be conducted. The implemented social distancing norms led to the adoption of virtual platforms for this purpose.

Moreover, the changes in policies during the pandemic, such as the relaxation of the regulations for telemedicine, and the improvements in the infrastructure supporting same-day home delivery of the under-investigation medications accelerated DCT platform adoption.

Sponsors and research agencies have aggressively worked to develop virtual platforms, to avoid any disruptions. Market players launched new solutions, brought certain updates to the existing ones, and leveraged digital health technologies, including telemedicine, to ensure the easy flow of research data.

Such breakthrough technologies have driven the virtual clinical trials market exponentially in recent years. Moreover, the clinical trial scenario is undergoing rapid changes with the usage of decentralized and virtual platforms and inclusion of more-remote elements, in response to the pandemic. Additionally, the market is growing with the increase in the spending by pharma companies on big data analytics and AI technologies, which are transforming the research and development process and, thus, lowering the associated cost.

Additionally, trials for the treatment of other diseases conducted during the pandemic had to deal with a lack of clinical data from on-site patients. To overcome this challenge, DCTs were initiated for numerous cancer drugs, an approach that is expected to become the norm in the coming years

Virtual Clinical Trials Market Analysis

Owing to the rising number of research and development activities centered around novel therapies and digitization at the laboratory level, the interventional category held the largest share, around 50%, in 2022, and it is expected to continue the same way during the forecast period.

Interventional studies, also called experimental research, allow the medical community to conclude the cause-and-effect relationships between an intervention or treatment. Such studies provide reliable evidence during epidemiological research on preventative or therapeutic products.

Geographical Analysis

North America To Dominate Market

North America dominated the global market, with around 40% share in 2022, attributed to the presence of several major market players. Moreover, the increasing adoption of advanced technologies in clinical research, rising R&D expenditure, and government support for drug R&D drive the market. For instance, the rate of new research project grant success increased by 1.6%, from 19.1% in 2021 to 20.7% in 2022. Additionally, in 2022, the NIH invested more than USD 43 billion in research to reduce the burden of illnesses.

Moreover, the contribution of the U.S. in the number of clinical trials registered around the world is the highest, at more than 31%. Additionally, more than 32% of the patient recruitment for such studies globally takes place in this country. The increasing number of registrations makes traditional methods of clinical trials obsolete; therefore, the virtual method is likely to be adopted in the coming years.

Report Breakdown

Based on Type

• Interventional         
• Observational        
• Expanded Access

Based on Indication

• Autoimmune Diseases          
• Cardiovascular Diseases       
• Metabolic Diseases
• Infectious Diseases
• Oncology
• Genitourinary         
• CNS       
• Ophthalmology

Based on Phase

• Phase I
• Phase II  
• Phase III 
• Phase IV

Geographical Analysis

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
• Asia-Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
• Latin America
  • Brazil
  • Mexico
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • U.A.E.

Virtual Clinical Trials Market Share

Decentralized solutions have brought clinical trials closer to the patient and transformed product development. As a result, market players are engaging in a range of strategic development to offer the best services, to make the trials efficient and cost-effective. For instance, Syneos Health signed a multiyear agreement with Microsoft in 2023, under which Syneos will utilize Microsoft Azure services to develop an analytics platform with AI, ML, and other technologies, to ensure advanced clinical trial services.

Additionally, Syneos Health and Science 37 signed a partnership agreement in 2021 to enhance decentralized clinical trial delivery. The companies aim to together offer a unified technology platform to streamline workflow, real-world evidence generation, and data harmonization for sponsors.

Similarly, ObvioHealth collaborated with Oracle in the APAC region in 2022. The alliance is aimed at enabling the rapid collection, integration, and analysis of multi-source data collected from sites, patients, devices, and labs.

Additionally, in 2022, the Medable Partner Network was launched. It brings together technology, service, data, site, and direct-to-patient partners, allowing all these aspects to work to accelerate decentralized clinical trials. It includes partnerships with Cognizant, Advanced Clinical, and CVS Health and expanded connections with Oracle, Parexel, PPD, Datavant, and other firms.